CKD5
Conditions
Interventions
Group 2:Erythropoietin
Sponsors
The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Aged >= 18 and = 3 months; 3) After the nature of the study was explained and the subjects had the opportunity to ask questions, the subjects voluntarily signed and dated the informed consent form approved by the ethics committee; 4) Patients with renal anemia, including patients who have previously received erythropoietin treatment and patients who can start using the above drugs based on the clinical judgment of the researchers.
Exclusion criteria
Exclusion criteria: 1) Previous history of aortic stenosis, hypertrophic obstructive cardiomyopathy, pericardial tamponade, acute and chronic pericarditis, constrictive pericarditis; 2) Acute coronary syndrome, severe arrhythmia and myocardial infarction occurred in the past 6 months; 3) Any other anemia caused by diseases other than CKD, such as thalassemia, sickle cell anemia, pure red cell aplasia, tumor related anemia, chemotherapy-related anemia, myelodysplastic syndrome, bleeding, malignant tumor, etc; 4) The patients who had been given oral roxestat for 6 months and who are taking salkubaltravalsartan orally; 5) Patients with a history of severe drug allergy or known hypersensitivity to active ingredients or excipients of rosalrestat; 6) Pregnant or lactating women, or women with fertility but unwilling to take contraceptive measures; 7) According to the researcher's judgment, the life expectancy was less than 12 months; 8) In the screening period, the patients with severe liver function abnormality met any of the following criteria: a) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 3 x ULN and total bilirubin >= 2 x ULN; b) ALT or ast > 8 x ULN; c) Total bilirubin >= 5 x ULN; 9) Patients who are participating in or will participate in other intervention studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular mass index;Cardiac ejection fraction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin;Iron index;Blood lipids;NT-proBNP; | — |
Countries
China
Contacts
Public ContactYang Jurong
The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital)
Outcome results
None listed